The chairs, Prof. Richard P. Baum and Prof. Frederik L. Giesel, guided participants through the latest scientific and clinical developments, shaping the future of Radiotheranostics. The first day focused on the rapidly advancing field of alpha emitters, with in-depth insights into key isotopes including Actinium (Ac), Astatine (At), and Lead (Pb) and their potential to transform targeted cancer therapy. On the second day, attention turned to innovative radiopharmaceutical targets, highlighting the emerging clinical impact of FAP, CA9, CXCR4, and GPC3 in diagnosis and treatment.